Drotaverine-Darnitsa is an isoquinoline derivative that exerts antispasmodic action on smooth muscle via inhibition of phosphodiesterase-4 (PDE4), resulting in an increase in the cAMP concentration and leading to smooth muscle relaxation due to inactivation of the myosin light chain kinase (MLCK). In vitro, drotaverine suppresses the action of PDE4 and inhibits isoenzymes phosphodiesterase-3 (PDE3) and phosphodiesterase-5 (PDE5).
Smooth muscle spasms in the biliary tract diseases: cholecystolithiasis, cholangiolithiasis, cholecystitis, pericholecystitis, cholangitis, papillitis.
Smooth muscle spasms in the urinary tract diseases: nephrolithiasis, urethrolithiasis, pyelitis, cystitis, vesical tenesmus.
As an adjuvant treatment (when it is impossible to use the drug in tablet form) in:
– Smooth muscle spasms in the gastrointestinal tract diseases: gastric and duodenal ulcers, gastritis, cardio- and/or pylorospasm, enteritis, colitis
– Gynecological diseases (dysmenorrhea)
Drotaverin-Darnitsa is used in adults in the daily dose of 40–240 mg for 1–3 single doses.
In acute colic, the drug is administered to adults intravenously slowly at a dose of 40–80 mg.
Drotaverine-Darnitsa is not used in children.